SBI Holdings, Inc. (“SBIH”), Tokyo, Japan, has indirectly acquired a 20% stake in Photonamic GmbH & Co. KG (“Photonamic”), seated in Wedel, Germany, from the financial investors Martin and Matthias Nixdorf. Photonamic is a subsidiary of the German pharmaceutical company medac GmbH, seated in Hamburg. The equity acquisition is to make Photonamic a joint venture between SBIH and medac. Capitalizing on this, Photonamic is expected to cooperate with SBI Pharmaceuticals Co., Ltd., a drug company engaged in biotechnology under the umbrella of the SBI Group.
Photonamic is engaged in research and development of drugs under the umbrella of medac that manufactures and sells an intraoperative diagnostic drug for brain tumors in Europe.
About SBI Group
SBI Group is a financial conglomerate extensively developing two principal segments that are (1) Asset Management Business and (2) Financial Services Business including brokerage and investment banking, commercial banking, and insurance. In addition to the above financial areas, SBIH, regarding the biotechnology-related business as the largest growth field of the SBI Group, is accelerating operations in Japan and abroad. Taking advantage of this investment in Photonamic, SBI Group will further accelerate operations in Europe, while continuously establishing a global business structure.
Advisor SBI Holdings
Dr. Christian Traichel (Leadpartner, Corporate/M&A, Munich), Dr. Bert Kimpel (Partner, Tax, Dusseldorf), Dr. Marco Hartmann-Rüppel (Partner, Merger Control, Hamburg), Dr. Manja Epping (Partner, Life Sciences & Healthcare, Munich), Dr. Arno Brokamp LL.M (Associate, Corporate/M&A, Munich), Dr. Philipp Ludewig (Associate, Merger control, Hamburg).